Artemether lumefantrine indications and usage: Difference between revisions

Jump to navigation Jump to search
(Created page with "__NOTOC__ {{Artemether lumefantrine}} {{CMG}}; {{AE}} {{chetan}} <ref name="dailymed.nlm.nih.gov">{{Cite web | last = | first = | title = COARTEM (ARTEMETHER AND LUMEF...")
 
No edit summary
 
Line 3: Line 3:
{{CMG}}; {{AE}} {{chetan}}
{{CMG}}; {{AE}} {{chetan}}


==Indications And Usage==


Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see Clinical Studies ].


===Limitations of Use===


 
Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria.
<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = COARTEM (ARTEMETHER AND LUMEFANTRINE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7866ec19-dfac-47d4-a53f-511a12643cbf | publisher =  | date =  | accessdate }}</ref>
Coartem Tablets are not approved for the prevention of malaria.<ref name="dailymed.nlm.nih.gov">{{Cite web  | last =  | first =  | title = COARTEM (ARTEMETHER AND LUMEFANTRINE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION] | url = http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7866ec19-dfac-47d4-a53f-511a12643cbf | publisher =  | date =  | accessdate }}</ref>





Latest revision as of 21:17, 6 January 2014

Artemether lumefantrine
(COARTEM®)FDA Package Insert
Description
Clinical Pharmacology
Microbiology
Indications and Usage
Contraindications
Warnings and Precautions
Adverse Reactions
Overdosage
Dosage and Administration
How Supplied
Labels and Packages

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Chetan Lokhande, M.B.B.S [2]

Indications And Usage

Coartem (artemether/lumefantrine) Tablets are indicated for treatment of acute, uncomplicated malaria infections due to Plasmodium falciparum in patients of 5 kg bodyweight and above. Coartem Tablets have been shown to be effective in geographical regions where resistance to chloroquine has been reported [see Clinical Studies ].

Limitations of Use

Coartem Tablets are not approved for patients with severe or complicated P. falciparum malaria. Coartem Tablets are not approved for the prevention of malaria.[1]


References

  1. "COARTEM (ARTEMETHER AND LUMEFANTRINE) TABLET [NOVARTIS PHARMACEUTICALS CORPORATION]". Text " accessdate " ignored (help)

Adapted from the FDA Package Insert.